SCN Launches Funding Competition to Support Translational Stem Cell Research Across Canada

June 21, 2019
Stem Cell Network

June 13, 2019 (Ottawa) The Stem Cell Network is pleased to launch a new national research funding competition comprised of four translational research programs in stem cell and regenerative medicine. The first round opened today to support innovative research that will ultimately realize both health and economic benefits for Canadians. Over the next three years, SCN … Continue reading SCN Launches Funding Competition to Support Translational Stem Cell Research Across Canada

Arbutus receives regulatory clearance to initiate Phase 1a/1b Clinical Trial of AB-7

June 20, 2019

– AB-729 is a subcutaneously-administered RNAi agent targeting HBV replication and HBsAg antigen production – Supports corporate objective to combine AB-729 with AB-506, Arbutus’ proprietary oral capsid inhibitor WARMINSTER, Pa., June 20, 2019 (GLOBE NEWSWIRE) — Arbutus Biopharma Corporation (Nasdaq: ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions company, today announced it has received regulatory clearance to initiate … Continue reading Arbutus receives regulatory clearance to initiate Phase 1a/1b Clinical Trial of AB-7

Arbutus to Participate at JMP Securities Life Sciences Conference

June 13, 2019

WARMINSTER, Pa., June 13, 2019 (GLOBE NEWSWIRE) — Arbutus Biopharma Corporation (Nasdaq: ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions company, today announced that Dr. Michael Sofia and Dr. Gaston Picchio will participate in a fireside chat at JMP Securities Life Sciences Conference at 10:00 am ET on Thursday, June 20, 2019. A live webcast of the fireside chat can be accessed through the Investors section of … Continue reading Arbutus to Participate at JMP Securities Life Sciences Conference

Arbutus to Participate at JMP Securities Life Sciences Conference

Arbutus Biopharma

WARMINSTER, Pa., June 13, 2019 (GLOBE NEWSWIRE) — Arbutus Biopharma Corporation (Nasdaq: ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions company, today announced that Dr. Michael Sofia and Dr. Gaston Picchio will participate in a fireside chat at JMP Securities Life Sciences Conference at 10:00 am ET on Thursday, June 20, 2019. A live webcast of the fireside chat can be accessed through the Investors section of … Continue reading Arbutus to Participate at JMP Securities Life Sciences Conference

Delmar Pharmaceuticals Updates The Terms Of Previously Announced Rights Offering

June 11, 2019

June 11, 2019 VANCOUVER, British Columbia and MENLO PARK, Calif., /PRNewswire/ — DelMar Pharmaceuticals, Inc. (NASDAQ: DMPI) (“DelMar” or the “Company”), a biopharmaceutical company focused on the development and commercialization of new cancer therapies, today announced that it has adjusted certain pricing information and key dates for its previously announced rights offering.  The subscription period … Continue reading Delmar Pharmaceuticals Updates The Terms Of Previously Announced Rights Offering

ASPECT BIOSYSTEMS PARTNERS WITH MERCK, GSK, AND MCGILL UNIVERSITY TO ENABLE DEVELOPMENT OF IMMUNO-ONCOLOGY THERAPEUTICS

June 10, 2019

ASPECT BIOSYSTEMS PARTNERS WITH MERCK, GSK, AND MCGILL UNIVERSITY TO ENABLE DEVELOPMENT OF IMMUNO-ONCOLOGY THERAPEUTICS This project will leverage Aspect Biosystems’ microfluidic 3D bioprinting platform to develop highly physiological, high-throughput tissues for the accurate and predictive screening of immuno-therapeutics targeting difficult-to-treat cancers such as triple negative breast cancer. Vancouver, BC, Canada – June 4, 2019 – … Continue reading ASPECT BIOSYSTEMS PARTNERS WITH MERCK, GSK, AND MCGILL UNIVERSITY TO ENABLE DEVELOPMENT OF IMMUNO-ONCOLOGY THERAPEUTICS

NZ Technologies announces third peer-reviewed paper on TIPSO touchless image navigation; builds evidence for a technology platform designed for the OR of the future

NZ Technologies announces third peer-reviewed paper on TIPSO touchless image navigation; builds evidence for a technology platform designed for the OR of the future Vancouver, Canada — June 4, 2019 — NZ Technologies Inc. (NZTech) is pleased to announce the publication of the third clinical review this year of its TIPSO™ technology. The paper highlights TIPSO’s … Continue reading NZ Technologies announces third peer-reviewed paper on TIPSO touchless image navigation; builds evidence for a technology platform designed for the OR of the future

Touchless image navigation facilitates decision-making in the operating room

Touchless image navigation facilitates decision-making in the operating room A recent publication confirms “the utility of touchless image navigation in the sterile field in facilitating decision-making and resource allocation during endovascular procedures.” The study, published in Minimally Invasive Therapy & Allied Technologies, provides the third clinical review of TIPSO technology (NZ Technologies), a human-computer interaction based … Continue reading Touchless image navigation facilitates decision-making in the operating room

DelMar Provides Clinical Update on VAL-083 from Ongoing First- and Second-Line Trials in Patients with MGMT-unmethylated Glioblastoma at a Key Opinion Leader Forum during the American Society of Clinical Oncology (ASCO) Annual Meeting

June 3, 2019

  VANCOUVER, British Columbia and MENLO PARK, Calif., June 3, 2019 /PRNewswire/ — DelMar Pharmaceuticals, Inc. (NASDAQ: DMPI) (“DelMar” or the “Company”), a biopharmaceutical company focused on the development of novel cancer therapies presented clinical updates from the Company’s ongoing first- and second-line trials in patients with MGMT-unmethylated glioblastoma multiforme (GBM) at a key opinion leader … Continue reading DelMar Provides Clinical Update on VAL-083 from Ongoing First- and Second-Line Trials in Patients with MGMT-unmethylated Glioblastoma at a Key Opinion Leader Forum during the American Society of Clinical Oncology (ASCO) Annual Meeting

Molecular You Named a 2019 Gartner ‘Cool Vendor’ in Healthcare Artificial Intelligence

Vancouver, May 21, 2019:  FOR IMMEDIATE RELEASE Molecular You Named a 2019 Gartner ‘Cool Vendor’ in Healthcare Artificial Intelligence The Cool Vendor report highlights interesting, new and innovative vendors, products and services.                  Vancouver, BC, May 21, 2019 /GlobeNewswire – Molecular You, a personalized digital health company, announced today that … Continue reading Molecular You Named a 2019 Gartner ‘Cool Vendor’ in Healthcare Artificial Intelligence